Clinical Trial

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Study acronym: IGCMU
Recruiting
View on ClinicalTrials.gov →
Summary
Only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. This hypothesis is reinforced by epidemiological studies revealing an excess risk of prostate cancer, thyroid cancer and leukemia in patients who have developed uveal melanoma, even though these cancers are not part of the tumor spectrum of known hereditary predispositions to uveal melanoma (BAP1, MBD4). The identification of new candidate genes, once validated, would enable us to offer these families appropriate surveillance.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-08-08; most recent amendment 2026-03-17.
Status change: Active, Not Recruiting → Recruiting 2026-03-17
Status change: Recruiting → Active, Not Recruiting 2025-11-27
Status change: Not Yet Recruiting → Recruiting 2024-10-31
Trial Details
NCT Number NCT06550674
Lead Sponsor Centre Jean Perrin
Collaborators: Association Nationale des Patients atteints de cancers de l'oeil (A.N.P.A.C.O.)
Conditions Uveal Melanoma
Enrollment 50 participants
Start Date 2024-10-29
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-19